Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

Current Treatment of Younger 1L AML in 2024

Gautam Borthakur

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Insights from 2024 EHA Annual Meeting

E. Angelucci

Current Treatment Landscape in BPDCN

Cristina Papayannidis

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl